Meeting
2017 ASCO Annual Meeting
A phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas.
Authors
Daniel H. Palmer
Department of Molecular and Clinical Cancer Medicine, University of Liverpool and Clatterbridge Cancer Centre, Liverpool, United Kingdom
Daniel H. Palmer , Svein Dueland , Juan W. Valle , Anne-Kirsti Aksnes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02261714
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4119)
DOI
10.1200/JCO.2017.35.15_suppl.4119
Abstract #
4119
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Adjuvant therapy in patients with resected pancreatic adenocarcinoma: Analysis of treatment allocation patterns in a Canadian provincial institution.
First Author: Manik Chahal
Poster
2015 ASCO Annual Meeting
A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.
First Author: Daniel H. Palmer
Poster
2015 ASCO Annual Meeting
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
First Author: Aaron James Scott
Poster
2013 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
First Author: Jeffrey Infante